ArticleFrontiers in oncology2025
Multiparametric magnetic resonance imaging-based comprehensive model on prediction of lymphovascular space invasion in cervical cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable ensemble learning model using intratumoral and peritumoral multi-sequence MR-radiomics predicts high-grade cervical cancer with lymphovascular space invasion.Frontiers in oncology · 2026Article
- An interpretable MRI radiomics approach for preoperative prediction of lymphovascular space invasion in cervical cancer using optimal peritumoral region.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a comprehensive model integrating multiparametric magnetic resonance imaging (MRI) radiomics and deep learning features for preoperative prediction of LVSI in early-stage cervical cancer. Methods: 155 patients from January 2019 to December 2023 were enrolled in this study and divided into the training and validation cohorts randomly at a ratio of 7:3. Radiomics and deep learning features were extracted from T2-weighted images (T2WI), apparent diffusion coefficient (ADC) maps, and late contrast-enhanced T1-weighted images (CE-T1WI). Mann-Whitney U test, the least absolute shrinkage and selection operator regression (LASSO) were used to select radiomics and deep learning features. Radiomics model (Rad model), deep learning model (DL model), and radiomics-deep learning model (RDL model) were derived from the training cohort using support vector machines (SVM) classifier. The prediction performances of the three models were evaluated with the area under the curve (AUC), calibration curve, decision curve analysis (DCA) and tested in the validation cohort. Results: The RDL model achieved predictive performance for LVSI in cervical cancer with an AUC of 0.968 (95% confidence interval (CI): 0.938-0.999) in the training cohort, higher than 0.801(95% CI: 0.712-0.891) of Rad model and 0.902(95 CI: 0.845-0.959) of DL model with statistical significance after Bonferroni correction. In the validation cohort, the predictive performance of the fusion model (RDL)(AUC = 0.859, 95% CI 0.751-0.967) was significantly superior to that of the single model (AUC of DL Model = 0.745 95% CI 0.595-0.894; AUC of Rad Model = 0.686 95% CI 0.525-0.847, P < 0.001), however, the DL and radiomics models did not demonstrate statistically significant differences in performance within the validation cohort (Delong test, P>0.05). Analysis of the calibration and decision curves indicated superior predictive precision and net clinical benefit for the RDL model relative to the others. Conclusions: The advanced RDL model demonstrated strong predictive accuracy for LVSI in cervical cancer, suggesting its promising role as a noninvasive imaging biomarker. This tool could significantly enhance preoperative treatment planning by providing reliable insights without invasive procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.